Effect of bleomycin-radiotherapy combination in management of head and neck squamous cell carcinoma

Shah, Pankaj; Shukla, Shilin N.; Patel, Keval; Patel, Nikunj; Baboo, H. A.; Patel, Dev

doi:10.1002/1097-0142(19810901)48:5<1106::aid-cncr2820480510>3.0.co;2-q

Cited by 16 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, when administered concomitantly with radiation therapy, bleomycin did not increase either response rate or survival time when compared to radiation therapy alone. Severe mucosal reactions in the majority of patients required discontinuation of therapy (Shah et al, 1981). The lack of haematopoietic and hepatic toxicities suggested that bleomycin could be used in combination with other drugs giving significant response rates in patients with previously treated SCCHN (Ervin et al, 1981).…”

mentioning

confidence: 96%

Platinum complexes inhibit repair of potentially lethal damage following bleomycin treatment

1987

View full text Add to dashboard Cite

Summary The SCC-25 cell line is a well-established line derived from a human squamous carcinoma of the head and neck. The capacity of this cell line for recovery from potentially lethal damage following X-ray treatment has been documented. The survival curve of stationary phase SCC-25 cells exposed to various concentrations of bleomycin is biphasic with an initial sensitive phase and a less sensitive second phase as is common for many cell lines. Stationary phase SCC-25 cells were exposed to lOOmUml-1 of bleomycin for I h. The drug was removed and the cells were allowed various periods to recover from potentially lethal damage. After 24h, the SCC-25 cells showed a recovery ratio (RIRO) of 7.0 which corresponded to an immediate survival at a drug level of 27mUml-1, a dose 3.7-fold less than the exposure concentration of 100mUml-. Over the course of the first 4h following bleomycin exposure, 0.5pM CDDP was a very effective inhibitor of potentially lethal damage repair, giving a R/Ro of 1

show abstract

mentioning

confidence: 96%

Platinum complexes inhibit repair of potentially lethal damage following bleomycin treatment

1987

View full text Add to dashboard Cite

show abstract

Preirradiation Chemotherapy for Advanced Head and Neck Carcinomas

Kukla¹,

Mantravadi²,

Applebaum³

et al. 1984

Archives of Otolaryngology - Head and Neck Surgery

View full text Add to dashboard Cite

The incidence of metastases after multimodal therapy for cancer of the head and neck

Slotman¹,

Mohit²,

Raina³

et al. 1984

Cancer

View full text Add to dashboard Cite

Combined therapeutic regimens integrating chemotherapy, radiation therapy, and surgery are reported to be effective in treating advanced squamous cell carcinomas of the head and neck. The current study evaluates 58 consecutive patients with advanced (T4, N3) head and neck cancers. Forty patients (multimodal group) were treated with 2 courses of chemotherapy (cisplatin 2 mg/kg; methotrexate 280–560 mg/m2 with leucovorin rescue; bleomycin 30 μ ×3) followed by radiation therapy and surgery. Eighteen patients (combined group) were treated with preoperative radiation therapy followed by surgery. In the multimodal group there were 27 (67.5%) partial responses and nine (22.5%) complete responses, for an overall response rate of 90%. Response rates by site of primary lesion were: oral cavity, 11 of 11; oropharynx, 13 of 17; hypopharynx, 5 to 5; and larynx 7 of 7. Distant metastases (skin, lung, bone, central nervous system [CNS]) appeared in 16 patients (40%) (P < 0.05 versus combined) at a median time of 8.5 months after diagnosis, 15 in patients having a partial (11) or complete (4) response. Thirteen patients (33%) developed distant metastases within 1 year of diagnosis (P < 0.05 versus combined). In 11 of these patients, the primary lesion and neck disease were resectable. Two thoracotomies were performed for solitary pulmonary metastases; one was resected for cure. Fifteen patients (38%) underwent curative resection; 11 (73%) were alive at 1 year, and ten (67%) were free of disease. Overall survival was 20 of 40 (50%) at 1 year. In the combined group, there were 14 partial responses (78%) and no complete responses. Early distant metastases appeared in two patients (12.5%), at 2 and 6 months after diagnosis. Seven patients (38%) underwent curative resection; six of seven (86%) were alive at 1 year, four of seven (57%) were disease‐free. Six of 16 patients at risk (37.5%) survived 1 year. After combined therapy, six of ten patients (60%) with responses to therapy survived 1 year versus 12 of 20 responders (57%) without distant metastases in the multimodal group. It is concluded that multimodal therapy for advanced head and neck cancer results in a higher response rate than with conventional combined therapy. The incidence of early and postoperative distant metastases was increased after the multimodal regimen. At 1 year there were no differences in survival between the combined and multimodal groups for responders without early metastases. Further observation is needed to determine the net long‐term effects of this regimen. A prospective randomized comparison of combined and multimodal therapy for advanced lesions is indicated.

show abstract

Effect of bleomycin-radiotherapy combination in management of head and neck squamous cell carcinoma

Cited by 16 publications

References 6 publications

Platinum complexes inhibit repair of potentially lethal damage following bleomycin treatment

Platinum complexes inhibit repair of potentially lethal damage following bleomycin treatment

Preirradiation Chemotherapy for Advanced Head and Neck Carcinomas

The incidence of metastases after multimodal therapy for cancer of the head and neck

Contact Info

Product

Resources

About